慢性疾患に対する戦略

Same author

Reply to the Letter to the Editor: Response to Concerns Raised on MRI Surveillance and Clinical Implications of ARIA in Disease Modifying Treatment.

The journal of prevention of Alzheimer's disease·2024

Same author

Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.

The journal of prevention of Alzheimer's disease·2023

Same author

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Diabetes & metabolism·2017

Same author

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Diabetes & metabolism·2017

Same author

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).

Diabetes & metabolism·2017

Same author

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).

Diabetes, obesity & metabolism·2015

Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026

Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026

Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026

Same journal

Documenting hospice care.

Lancet (London, England)·2026

Same journal

After the wood chipper.

Lancet (London, England)·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

関連する実験動画

慢性疾患に対する戦略

関連する概念動画

Reply to the Letter to the Editor: Response to Concerns Raised on MRI Surveillance and Clinical Implications of ARIA in Disease Modifying Treatment.

Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

関連する実験動画

慢性疾患に対する戦略

関連する概念動画

関連記事

Reply to the Letter to the Editor: Response to Concerns Raised on MRI Surveillance and Clinical Implications of ARIA in Disease Modifying Treatment.

Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.